fda glp-1 warning november 2025 Drug Recalls and Warnings: Illegal Sales and Misleading Marketing by Novo Nordisk and Eli Lilly GLP-1 Pipeline Update: August 2025
Description
In any case, Pfizers move narrowed Novos monopoly on sales (especially in the U.S.)
In contrast, information regarding GIP secretion in response to BTR stimulation is limited (Table 2)
Your healthcare provider may be able to request prior authorization from the insurance company on the basis that Wegovy is medically necessary
The medication is clinically identical in mechanism: it activates the GLP-1 and GIP receptors in the brain to reduce appetite and stabilize blood sugar
